These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 1819151)

  • 21. Analysis of interactions responsible for vasopressin binding to human neurohypophyseal hormone receptors-molecular dynamics study of the activated receptor-vasopressin-G(alpha) systems.
    Slusarz MJ; Giełdoń A; Slusarz R; Ciarkowski J
    J Pept Sci; 2006 Mar; 12(3):180-9. PubMed ID: 16114100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of amino acid determinants of dopamine 2 receptor synthetic agonist function.
    Al-Fulaij MA; Ren Y; Beinborn M; Kopin AS
    J Pharmacol Exp Ther; 2007 Apr; 321(1):298-307. PubMed ID: 17204745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A theoretical study to investigate D2DAR/D4DAR selectivity: receptor modeling and molecular docking of dopaminergic ligands.
    Ortore G; Tuccinardi T; Bertini S; Martinelli A
    J Med Chem; 2006 Feb; 49(4):1397-407. PubMed ID: 16480275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SH3 binding domains in the dopamine D4 receptor.
    Oldenhof J; Vickery R; Anafi M; Oak J; Ray A; Schoots O; Pawson T; von Zastrow M; Van Tol HH
    Biochemistry; 1998 Nov; 37(45):15726-36. PubMed ID: 9843378
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Homology models of mu-opioid receptor with organic and inorganic cations at conserved aspartates in the second and third transmembrane domains.
    Zhorov BS; Ananthanarayanan VS
    Arch Biochem Biophys; 2000 Mar; 375(1):31-49. PubMed ID: 10683246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modeling of the D2 dopamine receptor arylpiperazine binding site for 1-[2-[5-(1H-benzimidazole-2-thione)]ethyl]-4-arylpiperazines.
    Sukalović V; Zlatović M; Andrić D; Roglić G; Kostić-Rajaccić S; Soskić V
    Arch Pharm (Weinheim); 2004 Sep; 337(9):502-12. PubMed ID: 15362123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atypical and typical antipsychotic drug interactions with the dopamine D2 receptor.
    Hjerde E; Dahl SG; Sylte I
    Eur J Med Chem; 2005 Feb; 40(2):185-94. PubMed ID: 15694653
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of hydrogen bonds of ecdysteroids in the ligand-receptor interactions using a protein modeling system.
    Harada T; Nakagawa Y; Akamatsu M; Miyagawa H
    Bioorg Med Chem; 2009 Aug; 17(16):5868-73. PubMed ID: 19631551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of a chimeric human dopamine D3/D2 receptor functionally coupled to adenylyl cyclase in Chinese hamster ovary cells.
    Van Leeuwen DH; Eisenstein J; O'Malley K; MacKenzie RG
    Mol Pharmacol; 1995 Aug; 48(2):344-51. PubMed ID: 7651368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complementarity of delta opioid ligand pharmacophore and receptor models.
    Mosberg HI
    Biopolymers; 1999; 51(6):426-39. PubMed ID: 10797231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Investigation of mechanism of desmopressin binding in vasopressin V2 receptor versus vasopressin V1a and oxytocin receptors: molecular dynamics simulation of the agonist-bound state in the membrane-aqueous system.
    Slusarz MJ; Slusarz R; Ciarkowski J
    Biopolymers; 2006 Apr; 81(5):321-38. PubMed ID: 16333859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sequence-derived three-dimensional pharmacophore models for G-protein-coupled receptors and their application in virtual screening.
    Klabunde T; Giegerich C; Evers A
    J Med Chem; 2009 May; 52(9):2923-32. PubMed ID: 19374402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Modeling of hormonal receptors. Application to drug design].
    Hibert MF; Trumpp-Kallmeyer S; Bruinvels AT; Hoflack J
    Therapie; 1991; 46(6):445-51. PubMed ID: 1668042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular dynamics of serotonin and ritanserin interacting with the 5-HT2 receptor.
    Edvardsen O; Sylte I; Dahl SG
    Brain Res Mol Brain Res; 1992 Jul; 14(3):166-78. PubMed ID: 1331649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular dynamics of the 5-HT1a receptor and ligands.
    Sylte I; Edvardsen O; Dahl SG
    Protein Eng; 1993 Sep; 6(7):691-700. PubMed ID: 8248092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular structure and dynamics of cis(Z)-and trans(E)-flupenthixol and clopenthixol.
    Sylte I; Dahl SG
    Pharm Res; 1991 Apr; 8(4):462-70. PubMed ID: 1871040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural changes by sulfoxidation of phenothiazine drugs.
    Dahl SG; Kollman PA; Rao SN; Singh UC
    J Comput Aided Mol Des; 1992 Jun; 6(3):207-22. PubMed ID: 1355521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modelling drugs and receptors using potentials: examples in the GPCRs' domain.
    Carpy A; Rusig I; Laguerre M
    SAR QSAR Environ Res; 2001; 12(6):497-513. PubMed ID: 11813802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular modelling of D2-like dopamine receptors.
    Livingstone CD; Strange PG; Naylor LH
    Biochem J; 1992 Oct; 287 ( Pt 1)(Pt 1):277-82. PubMed ID: 1358063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular structure and dynamics of the four 10-hydroxynortriptyline isomers.
    Heimstad E; Edvardsen O; Dahl SG
    Neuropsychopharmacology; 1992 May; 6(3):137-44. PubMed ID: 1599604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.